<?xml version='1.0' encoding='utf-8'?>
<document id="30745392"><sentence text="Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers."><entity charOffset="123-132" id="DDI-PubMed.30745392.s1.e0" text="Ritonavir" /><entity charOffset="134-144" id="DDI-PubMed.30745392.s1.e1" text="Atazanavir" /><entity charOffset="146-155" id="DDI-PubMed.30745392.s1.e2" text="Lopinavir" /><entity charOffset="161-170" id="DDI-PubMed.30745392.s1.e3" text="Darunavir" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e0" e2="DDI-PubMed.30745392.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e0" e2="DDI-PubMed.30745392.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e0" e2="DDI-PubMed.30745392.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e0" e2="DDI-PubMed.30745392.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e1" e2="DDI-PubMed.30745392.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e1" e2="DDI-PubMed.30745392.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e1" e2="DDI-PubMed.30745392.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e2" e2="DDI-PubMed.30745392.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s1.e2" e2="DDI-PubMed.30745392.s1.e3" /></sentence><sentence text="The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfected with human immunodeficiency virus (HIV)" /><sentence text=" We explored the pharmacokinetic interactions of elbasvir and grazoprevir with ritonavir and ritonavir-boosted HIV protease inhibitors in three phase 1 trials"><entity charOffset="49-57" id="DDI-PubMed.30745392.s3.e0" text="elbasvir" /><entity charOffset="62-73" id="DDI-PubMed.30745392.s3.e1" text="grazoprevir" /><entity charOffset="79-88" id="DDI-PubMed.30745392.s3.e2" text="ritonavir" /><entity charOffset="93-102" id="DDI-PubMed.30745392.s3.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e0" e2="DDI-PubMed.30745392.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e0" e2="DDI-PubMed.30745392.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e0" e2="DDI-PubMed.30745392.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e0" e2="DDI-PubMed.30745392.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e1" e2="DDI-PubMed.30745392.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e1" e2="DDI-PubMed.30745392.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e1" e2="DDI-PubMed.30745392.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e2" e2="DDI-PubMed.30745392.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s3.e2" e2="DDI-PubMed.30745392.s3.e3" /></sentence><sentence text=" Drug-drug interaction trials with healthy participants were conducted to evaluate the effect of ritonavir on the pharmacokinetics of grazoprevir (n = 10) and the potential two-way pharmacokinetic interactions of elbasvir (n = 30) or grazoprevir (n = 39) when coadministered with ritonavir-boosted atazanavir, lopinavir, or darunavir"><entity charOffset="97-106" id="DDI-PubMed.30745392.s4.e0" text="ritonavir" /><entity charOffset="134-145" id="DDI-PubMed.30745392.s4.e1" text="grazoprevir" /><entity charOffset="213-221" id="DDI-PubMed.30745392.s4.e2" text="elbasvir" /><entity charOffset="234-245" id="DDI-PubMed.30745392.s4.e3" text="grazoprevir" /><entity charOffset="280-289" id="DDI-PubMed.30745392.s4.e4" text="ritonavir" /><entity charOffset="298-308" id="DDI-PubMed.30745392.s4.e5" text="atazanavir" /><entity charOffset="310-319" id="DDI-PubMed.30745392.s4.e6" text="lopinavir" /><entity charOffset="324-333" id="DDI-PubMed.30745392.s4.e7" text="darunavir" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e0" e2="DDI-PubMed.30745392.s4.e7" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e1" e2="DDI-PubMed.30745392.s4.e7" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e2" e2="DDI-PubMed.30745392.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e2" e2="DDI-PubMed.30745392.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e2" e2="DDI-PubMed.30745392.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e2" e2="DDI-PubMed.30745392.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e2" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e2" e2="DDI-PubMed.30745392.s4.e7" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e3" e2="DDI-PubMed.30745392.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e3" e2="DDI-PubMed.30745392.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e3" e2="DDI-PubMed.30745392.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e3" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e3" e2="DDI-PubMed.30745392.s4.e7" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e4" e2="DDI-PubMed.30745392.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e4" e2="DDI-PubMed.30745392.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e4" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e4" e2="DDI-PubMed.30745392.s4.e7" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e5" e2="DDI-PubMed.30745392.s4.e5" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e5" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e5" e2="DDI-PubMed.30745392.s4.e7" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e6" e2="DDI-PubMed.30745392.s4.e6" /><pair ddi="false" e1="DDI-PubMed.30745392.s4.e6" e2="DDI-PubMed.30745392.s4.e7" /></sentence><sentence text=" Coadministration of ritonavir with grazoprevir increased grazoprevir exposure; the geometric mean ratio (GMR) for grazoprevir plus ritonavir versus grazoprevir alone area under the concentration-time curve from 0 to 24 h (AUC0-24) was 1"><entity charOffset="21-30" id="DDI-PubMed.30745392.s5.e0" text="ritonavir" /><entity charOffset="36-47" id="DDI-PubMed.30745392.s5.e1" text="grazoprevir" /><entity charOffset="58-69" id="DDI-PubMed.30745392.s5.e2" text="grazoprevir" /><entity charOffset="132-141" id="DDI-PubMed.30745392.s5.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e0" e2="DDI-PubMed.30745392.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e0" e2="DDI-PubMed.30745392.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e0" e2="DDI-PubMed.30745392.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e0" e2="DDI-PubMed.30745392.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e1" e2="DDI-PubMed.30745392.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e1" e2="DDI-PubMed.30745392.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e1" e2="DDI-PubMed.30745392.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e2" e2="DDI-PubMed.30745392.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s5.e2" e2="DDI-PubMed.30745392.s5.e3" /></sentence><sentence text="91 (90% confidence interval [CI]; 1" /><sentence text="31 to 2" /><sentence text="79)" /><sentence text=" Grazoprevir exposure was markedly increased with coadministration of atazanavir-ritonavir, lopinavir-ritonavir, and darunavir-ritonavir, with GMRs for grazoprevir AUC0-24 of 10"><entity charOffset="1-12" id="DDI-PubMed.30745392.s9.e0" text="Grazoprevir" /><entity charOffset="70-80" id="DDI-PubMed.30745392.s9.e1" text="atazanavir" /><entity charOffset="143-147" id="DDI-PubMed.30745392.s9.e2" text="GMRs" /><entity charOffset="152-163" id="DDI-PubMed.30745392.s9.e3" text="grazoprevir" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e0" e2="DDI-PubMed.30745392.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e0" e2="DDI-PubMed.30745392.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e0" e2="DDI-PubMed.30745392.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e0" e2="DDI-PubMed.30745392.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e1" e2="DDI-PubMed.30745392.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e1" e2="DDI-PubMed.30745392.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e1" e2="DDI-PubMed.30745392.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e2" e2="DDI-PubMed.30745392.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s9.e2" e2="DDI-PubMed.30745392.s9.e3" /></sentence><sentence text="58 (90% CI, 7" /><sentence text="78 to 14" /><sentence text="39), 12" /><sentence text="86 (90% CI, 10" /><sentence text="25 to 16" /><sentence text="13), and 7" /><sentence text="50 (90% CI, 5" /><sentence text="92 to 9" /><sentence text="51), respectively" /><sentence text=" Elbasvir exposure was increased with coadministration of atazanavir-ritonavir, lopinavir-ritonavir, and darunavir-ritonavir, with GMRs for elbasvir AUC0-24 of 4"><entity charOffset="58-68" id="DDI-PubMed.30745392.s19.e0" text="atazanavir" /><entity charOffset="131-135" id="DDI-PubMed.30745392.s19.e1" text="GMRs" /><pair ddi="false" e1="DDI-PubMed.30745392.s19.e0" e2="DDI-PubMed.30745392.s19.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s19.e0" e2="DDI-PubMed.30745392.s19.e1" /></sentence><sentence text="76 (90% CI, 4" /><sentence text="07 to 5" /><sentence text="56), 3" /><sentence text="71 (90% CI, 3" /><sentence text="05 to 4" /><sentence text="53), and 1" /><sentence text="66 (90% CI, 1" /><sentence text="35 to 2" /><sentence text="05), respectively" /><sentence text=" Grazoprevir and elbasvir had little effect on atazanavir, lopinavir, and darunavir pharmacokinetics"><entity charOffset="1-12" id="DDI-PubMed.30745392.s29.e0" text="Grazoprevir" /><entity charOffset="17-25" id="DDI-PubMed.30745392.s29.e1" text="elbasvir" /><entity charOffset="47-57" id="DDI-PubMed.30745392.s29.e2" text="atazanavir" /><entity charOffset="59-68" id="DDI-PubMed.30745392.s29.e3" text="lopinavir" /><entity charOffset="74-83" id="DDI-PubMed.30745392.s29.e4" text="darunavir" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e0" e2="DDI-PubMed.30745392.s29.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e0" e2="DDI-PubMed.30745392.s29.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e0" e2="DDI-PubMed.30745392.s29.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e0" e2="DDI-PubMed.30745392.s29.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e0" e2="DDI-PubMed.30745392.s29.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e1" e2="DDI-PubMed.30745392.s29.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e1" e2="DDI-PubMed.30745392.s29.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e1" e2="DDI-PubMed.30745392.s29.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e1" e2="DDI-PubMed.30745392.s29.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e2" e2="DDI-PubMed.30745392.s29.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e2" e2="DDI-PubMed.30745392.s29.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e2" e2="DDI-PubMed.30745392.s29.e4" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e3" e2="DDI-PubMed.30745392.s29.e3" /><pair ddi="false" e1="DDI-PubMed.30745392.s29.e3" e2="DDI-PubMed.30745392.s29.e4" /></sentence><sentence text=" Coadministration of elbasvir-grazoprevir with atazanavir-ritonavir, lopinavir-ritonavir, or darunavir-ritonavir is contraindicated, owing to an increase in grazoprevir exposure"><entity charOffset="47-57" id="DDI-PubMed.30745392.s30.e0" text="atazanavir" /><entity charOffset="69-78" id="DDI-PubMed.30745392.s30.e1" text="lopinavir" /><entity charOffset="93-112" id="DDI-PubMed.30745392.s30.e2" text="darunavir-ritonavir" /><pair ddi="false" e1="DDI-PubMed.30745392.s30.e0" e2="DDI-PubMed.30745392.s30.e0" /><pair ddi="false" e1="DDI-PubMed.30745392.s30.e0" e2="DDI-PubMed.30745392.s30.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s30.e0" e2="DDI-PubMed.30745392.s30.e2" /><pair ddi="false" e1="DDI-PubMed.30745392.s30.e1" e2="DDI-PubMed.30745392.s30.e1" /><pair ddi="false" e1="DDI-PubMed.30745392.s30.e1" e2="DDI-PubMed.30745392.s30.e2" /></sentence><sentence text=" Therefore, HIV treatment regimens without HIV protease inhibitors should be considered for HCV/HIV-coinfected individuals who are being treated with elbasvir-grazoprevir" /><sentence text="" /></document>